Prosecution Insights
Last updated: April 19, 2026

Examiner: GRABER, JAMES J

Tech Center 1600 • Art Units: 1631 1633

This examiner grants 46% of resolved cases

Performance Statistics

46.4%
Allow Rate
-13.6% vs TC avg
221
Total Applications
+57.3%
Interview Lift
1386
Avg Prosecution Days
Based on 181 resolved cases, 2023–2026

Rejection Statute Breakdown

5.1%
§101 Eligibility
15.4%
§102 Novelty
32.3%
§103 Obviousness
28.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17913540 Compositions and Methods for Treatment Non-Final OA The Regents of the University of California
18248193 PRODUCTION OF MEGAKARYOCYTES AND PLATELETS IN A CO-CULTURE SYSTEM Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
18010773 TARGETING THE HUMAN CCR5 LOCUS AS A SAFE HARBOR FOR THE EXPRESSION OF THERAPEUTIC PROTEINS Non-Final OA The Board of Trustees of the Leland Stanford Junior University
18449100 GENERATION OF INDUCED PLURIPOTENT STEM CELLS FROM SMALL VOLUMES OF PERIPHERAL BLOOD Non-Final OA FUJIFILM Cellular Dynamics, Inc.
18309370 CELLS EXPRESSING MULTIPLE CHIMERIC ANTIGEN RECEPTOR (CAR) MOLECULES AND USES THEREFORE Final Rejection The Trustees of the University of Pennsylvania
17580219 INCREASING GENOME STABILITY AND REPROGRAMMING EFFICIENCY OF INDUCED PLURIPOTENT STEM CELLS Non-Final OA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
17637760 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH Non-Final OA DUKE UNIVERSITY
18170671 PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED NATURAL KILLER CELLS AND ANTIGEN-SPECIFIC T CELLS, MANUFACTURING METHOD THEREOF, AND METHOD OF USING THE SAME Non-Final OA NATIONAL YANG MING CHIAO TUNG UNIVERSITY
18517402 METHOD FOR PREPARING BROWN ADIPOCYTE Non-Final OA KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
17911018 COMPOSITION FOR INDUCING APOPTOSIS OF CELLS HAVING GENOMIC SEQUENCE VARIATION AND METHOD FOR INDUCING APOPTOSIS OF CELLS BY USING COMPOSITION Non-Final OA UNIST (ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY)
17759832 MICRORNA-7 COMPOSITIONS FOR PROMOTING FUNCTIONAL RECOVERY FOLLOWING SPINAL CORD INJURY AND METHODS OF USE THEREOF Final Rejection Rutgers, The State University of New Jersey
17782924 A HEMOSTATIC AGENT AND USES THEREOF Final Rejection ROYAL COLLEGE OF SURGEONS IN IRELAND
18424395 BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS Final Rejection City of Hope
17430382 MODIFIED NATURAL KILLER (NK) CELLS FOR IMMUNOTHERAPY Non-Final OA Editas Medicine, Inc.
17799239 BCMA-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND METHODS AND USES THEREOF Non-Final OA Juno Therapeutics, Inc.
17767687 Chimeric Cytokine Receptors Non-Final OA UVic Industry Partnerships Inc.
18235476 VISIBLE LIGHT POLYMERIZATION OF POLYETHYLENE GLYCOL (PEG) HYDROGELS Non-Final OA STEM PHARM, INCORPORATED
18359916 NON-INVASIVE METHOD FOR GENERATING HUMAN THREE-DIMENSIONAL AND TWO- DIMENSIONAL NASOPHARYNGEAL ORGANOIDS Non-Final OA Centre for Immunology & Infection Limited
15780542 SCALABLE METHODS FOR PRODUCING RECOMBINANT ADENO-ASSOCIATED VIRAL (AAV) VECTOR IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR CLINICAL USE Final Rejection SPARK THERAPEUTICS, INC.
18300852 NATURAL KILLER CELL HAVING CONTROLLED ONCOLOGY-RELEATED GENE EXPRESSION, AND USE THEREOF Non-Final OA CHA BIOLAB CO., LTD.
18043501 CELL PREPARATION FOR USE IN SUPPRESSING MUSCLE MASS LOSS Non-Final OA HUMAN LIFE CORD JAPAN INC.
17907318 METHOD FOR OBTAINING ENDOMETRIAL MESENCHYMAL STEM CELLS FROM HUMAN MENSTRUAL BLOOD Non-Final OA SHANGHAI WOLWO STEM CELL TECHNOLOGY CO., LTD.
17822767 METHODS FOR EX VIVO ENRICHMENT AND EXPANSION OF TUMOR REACTIVE T CELLS AND RELATED COMPOSITIONS THEREOF Final Rejection TURNSTONE BIOLOGICS CORP.
17258533 USE OF IL-12 TO ALTER EPIGENETIC EFFECTOR PROGRAMS IN CD8 T CELLS Non-Final OA St. Jude Children's Research Hospital
15779869 METHOD FOR PRODUCING MESENCHYMAL STEM CELLS Final Rejection TAKARA BIO INC.
17620047 ROTAVIRUS MRNA VACCINE Final Rejection CureVac AG
17632938 COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF AGENTS Non-Final OA Moderna TX, Inc.
17603935 MONITORING GENE THERAPY Non-Final OA LogicBio Therapeutics, Inc.
17288041 Porcine Scaffolds and Methods of Preparation Non-Final OA Convatec Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month